Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Type 2 diabetes increases the risk of coronary heart disease (CHD) 2-4-fold, making CHD the predominant cause of death in patients with diabetes. Currently identified risk factors include, among others, hyperglycaemia, hypertension and dyslipidaemia. Since studies show that intensive glycaemic control alone will not overcome the excess CHD risk, reducing blood pressure by any means and lipid levels by using statins and fibrates is effective in reducing CHD and associated mortality in patients with type 2 diabetes. Other interventions include aspirin therapy and the use of angiotensin-converting enzyme (ACE) inhibitors.

Original publication




Conference paper

Publication Date



61 Suppl 1


S3 - S8


Angioplasty, Balloon, Coronary, Anticholesteremic Agents, Antihypertensive Agents, Aspirin, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Membrane Glycoproteins, Risk Factors